J Cartmell, J A Monn, D D Schoepp. J Pharmacol Exp Ther 1999
Times Cited: 245
Times Cited: 245
Times Cited
Times Co-cited
Similarity
Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.
B Moghaddam, B W Adams. Science 1998
B Moghaddam, B W Adams. Science 1998
69
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova,[...]. Nat Med 2007
Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova,[...]. Nat Med 2007
67
A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity.
Ruggero Galici, Nicholas G Echemendia, Alice L Rodriguez, P Jeffrey Conn. J Pharmacol Exp Ther 2005
Ruggero Galici, Nicholas G Echemendia, Alice L Rodriguez, P Jeffrey Conn. J Pharmacol Exp Ther 2005
37
Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).
Matthew J Fell, Kjell A Svensson, Bryan G Johnson, Darryle D Schoepp. J Pharmacol Exp Ther 2008
Matthew J Fell, Kjell A Svensson, Bryan G Johnson, Darryle D Schoepp. J Pharmacol Exp Ther 2008
36
The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity.
M L Woolley, D J Pemberton, S Bate, C Corti, D N C Jones. Psychopharmacology (Berl) 2008
M L Woolley, D J Pemberton, S Bate, C Corti, D N C Jones. Psychopharmacology (Berl) 2008
32
Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268.
D S Lorrain, C S Baccei, L J Bristow, J J Anderson, M A Varney. Neuroscience 2003
D S Lorrain, C S Baccei, L J Bristow, J J Anderson, M A Varney. Neuroscience 2003
30
Regulation of neurotransmitter release by metabotropic glutamate receptors.
J Cartmell, D D Schoepp. J Neurochem 2000
J Cartmell, D D Schoepp. J Neurochem 2000
29
Identification of a serotonin/glutamate receptor complex implicated in psychosis.
Javier González-Maeso, Rosalind L Ang, Tony Yuen, Pokman Chan, Noelia V Weisstaub, Juan F López-Giménez, Mingming Zhou, Yuuya Okawa, Luis F Callado, Graeme Milligan,[...]. Nature 2008
Javier González-Maeso, Rosalind L Ang, Tony Yuen, Pokman Chan, Noelia V Weisstaub, Juan F López-Giménez, Mingming Zhou, Yuuya Okawa, Luis F Callado, Graeme Milligan,[...]. Nature 2008
29
A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis.
Michael A Benneyworth, Zixiu Xiang, Randy L Smith, Efrain E Garcia, P Jeffrey Conn, Elaine Sanders-Bush. Mol Pharmacol 2007
Michael A Benneyworth, Zixiu Xiang, Randy L Smith, Efrain E Garcia, P Jeffrey Conn, Elaine Sanders-Bush. Mol Pharmacol 2007
27
Pharmacology and functions of metabotropic glutamate receptors.
P J Conn, J P Pin. Annu Rev Pharmacol Toxicol 1997
P J Conn, J P Pin. Annu Rev Pharmacol Toxicol 1997
26
Metabotropic glutamate receptors: physiology, pharmacology, and disease.
Colleen M Niswender, P Jeffrey Conn. Annu Rev Pharmacol Toxicol 2010
Colleen M Niswender, P Jeffrey Conn. Annu Rev Pharmacol Toxicol 2010
26
Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s).
Michael P Johnson, David Barda, Thomas C Britton, Renee Emkey, William J Hornback, G Erik Jagdmann, David L McKinzie, Eric S Nisenbaum, Joseph P Tizzano, Darryle D Schoepp. Psychopharmacology (Berl) 2005
Michael P Johnson, David Barda, Thomas C Britton, Renee Emkey, William J Hornback, G Erik Jagdmann, David L McKinzie, Eric S Nisenbaum, Joseph P Tizzano, Darryle D Schoepp. Psychopharmacology (Berl) 2005
26
In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.
Linda M Rorick-Kehn, Bryan G Johnson, Karen M Knitowski, Craig R Salhoff, Jeffrey M Witkin, Kenneth W Perry, Kelly I Griffey, Joseph P Tizzano, James A Monn, David L McKinzie,[...]. Psychopharmacology (Berl) 2007
Linda M Rorick-Kehn, Bryan G Johnson, Karen M Knitowski, Craig R Salhoff, Jeffrey M Witkin, Kenneth W Perry, Kelly I Griffey, Joseph P Tizzano, James A Monn, David L McKinzie,[...]. Psychopharmacology (Berl) 2007
26
Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.
J A Monn, M J Valli, S M Massey, M M Hansen, T J Kress, J P Wepsiec, A R Harkness, J L Grutsch, R A Wright, B G Johnson,[...]. J Med Chem 1999
J A Monn, M J Valli, S M Massey, M M Hansen, T J Kress, J P Wepsiec, A R Harkness, J L Grutsch, R A Wright, B G Johnson,[...]. J Med Chem 1999
25
The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing.
J Cartmell, J A Monn, D D Schoepp. Eur J Pharmacol 2000
J Cartmell, J A Monn, D D Schoepp. Eur J Pharmacol 2000
30
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.
John H Krystal, Walid Abi-Saab, Edward Perry, D Cyril D'Souza, Nianjin Liu, Ralitza Gueorguieva, Lisa McDougall, Tracy Hunsberger, Aysenil Belger, Louise Levine,[...]. Psychopharmacology (Berl) 2005
John H Krystal, Walid Abi-Saab, Edward Perry, D Cyril D'Souza, Nianjin Liu, Ralitza Gueorguieva, Lisa McDougall, Tracy Hunsberger, Aysenil Belger, Louise Levine,[...]. Psychopharmacology (Berl) 2005
24
Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.
P Jeffrey Conn, Craig W Lindsley, Carrie K Jones. Trends Pharmacol Sci 2009
P Jeffrey Conn, Craig W Lindsley, Carrie K Jones. Trends Pharmacol Sci 2009
24
Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice.
Ruggero Galici, Carrie K Jones, Kamondanai Hemstapat, Yi Nong, Nicholas G Echemendia, Lilly C Williams, Tomas de Paulis, P Jeffrey Conn. J Pharmacol Exp Ther 2006
Ruggero Galici, Carrie K Jones, Kamondanai Hemstapat, Yi Nong, Nicholas G Echemendia, Lilly C Williams, Tomas de Paulis, P Jeffrey Conn. J Pharmacol Exp Ther 2006
24
Recent advances in the phencyclidine model of schizophrenia.
D C Javitt, S R Zukin. Am J Psychiatry 1991
D C Javitt, S R Zukin. Am J Psychiatry 1991
24
Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors.
J C Gewirtz, G J Marek. Neuropsychopharmacology 2000
J C Gewirtz, G J Marek. Neuropsychopharmacology 2000
24
A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
Bruce J Kinon, Lu Zhang, Brian A Millen, Olawale O Osuntokun, Judy E Williams, Sara Kollack-Walker, Kimberley Jackson, Ludmila Kryzhanovskaya, Natalia Jarkova. J Clin Psychopharmacol 2011
Bruce J Kinon, Lu Zhang, Brian A Millen, Olawale O Osuntokun, Judy E Williams, Sara Kollack-Walker, Kimberley Jackson, Ludmila Kryzhanovskaya, Natalia Jarkova. J Clin Psychopharmacol 2011
24
Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine.
J Cartmell, J A Monn, D D Schoepp. Psychopharmacology (Berl) 2000
J Cartmell, J A Monn, D D Schoepp. Psychopharmacology (Berl) 2000
23
Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder.
Eduardo Dunayevich, Janelle Erickson, Louise Levine, Ronald Landbloom, Darryle D Schoepp, Gary D Tollefson. Neuropsychopharmacology 2008
Eduardo Dunayevich, Janelle Erickson, Louise Levine, Ronald Landbloom, Darryle D Schoepp, Gary D Tollefson. Neuropsychopharmacology 2008
22
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
J H Krystal, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney. Arch Gen Psychiatry 1994
J H Krystal, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney. Arch Gen Psychiatry 1994
22
Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.
Chantal Schlumberger, Daniela Schäfer, Caroline Barberi, Lorenzo Morè, Jens Nagel, Małgorzata Pietraszek, Werner J Schmidt, Wojciech Danysz. Behav Pharmacol 2009
Chantal Schlumberger, Daniela Schäfer, Caroline Barberi, Lorenzo Morè, Jens Nagel, Małgorzata Pietraszek, Werner J Schmidt, Wojciech Danysz. Behav Pharmacol 2009
30
Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine.
Michael P Johnson, Melvyn Baez, G Erik Jagdmann, Thomas C Britton, Thomas H Large, David O Callagaro, Joseph P Tizzano, James A Monn, Darryle D Schoepp. J Med Chem 2003
Michael P Johnson, Melvyn Baez, G Erik Jagdmann, Thomas C Britton, Thomas H Large, David O Callagaro, Joseph P Tizzano, James A Monn, Darryle D Schoepp. J Med Chem 2003
20
Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties.
J A Monn, M J Valli, S M Massey, R A Wright, C R Salhoff, B G Johnson, T Howe, C A Alt, G A Rhodes, R L Robey,[...]. J Med Chem 1997
J A Monn, M J Valli, S M Massey, R A Wright, C R Salhoff, B G Johnson, T Howe, C A Alt, G A Rhodes, R L Robey,[...]. J Med Chem 1997
20
Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.
G J Marek, R A Wright, D D Schoepp, J A Monn, G K Aghajanian. J Pharmacol Exp Ther 2000
G J Marek, R A Wright, D D Schoepp, J A Monn, G K Aghajanian. J Pharmacol Exp Ther 2000
20
Metabotropic glutamate receptors as novel targets for anxiety and stress disorders.
Chad J Swanson, Mark Bures, Michael P Johnson, Anni-Maija Linden, James A Monn, Darryle D Schoepp. Nat Rev Drug Discov 2005
Chad J Swanson, Mark Bures, Michael P Johnson, Anni-Maija Linden, James A Monn, Darryle D Schoepp. Nat Rev Drug Discov 2005
18
LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress.
Darryle D Schoepp, Rebecca A Wright, Louise R Levine, Brenda Gaydos, William Z Potter. Stress 2003
Darryle D Schoepp, Rebecca A Wright, Louise R Levine, Brenda Gaydos, William Z Potter. Stress 2003
18
Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge.
Daniel S Lorrain, Hervé Schaffhauser, Una C Campbell, Christopher S Baccei, Lucia D Correa, Blake Rowe, Dana E Rodriguez, Jeffery J Anderson, Mark A Varney, Anthony B Pinkerton,[...]. Neuropsychopharmacology 2003
Daniel S Lorrain, Hervé Schaffhauser, Una C Campbell, Christopher S Baccei, Lucia D Correa, Blake Rowe, Dana E Rodriguez, Jeffery J Anderson, Mark A Varney, Anthony B Pinkerton,[...]. Neuropsychopharmacology 2003
21
Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats.
Houman Homayoun, Mark E Jackson, Bita Moghaddam. J Neurophysiol 2005
Houman Homayoun, Mark E Jackson, Bita Moghaddam. J Neurophysiol 2005
17
The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations.
R S Petralia, Y X Wang, A S Niedzielski, R J Wenthold. Neuroscience 1996
R S Petralia, Y X Wang, A S Niedzielski, R J Wenthold. Neuroscience 1996
17
Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice.
W P Spooren, F Gasparini, H van der Putten, M Koller, S Nakanishi, R Kuhn. Eur J Pharmacol 2000
W P Spooren, F Gasparini, H van der Putten, M Koller, S Nakanishi, R Kuhn. Eur J Pharmacol 2000
19
Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
Linda M Rorick-Kehn, Bryan G Johnson, Jennifer L Burkey, Rebecca A Wright, David O Calligaro, Gerard J Marek, Eric S Nisenbaum, John T Catlow, Ann E Kingston, Deborah D Giera,[...]. J Pharmacol Exp Ther 2007
Linda M Rorick-Kehn, Bryan G Johnson, Jennifer L Burkey, Rebecca A Wright, David O Calligaro, Gerard J Marek, Eric S Nisenbaum, John T Catlow, Ann E Kingston, Deborah D Giera,[...]. J Pharmacol Exp Ther 2007
20
The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat.
Caitlin A Jones, Angus M Brown, Dorothee P Auer, Kevin C F Fone. Psychopharmacology (Berl) 2011
Caitlin A Jones, Angus M Brown, Dorothee P Auer, Kevin C F Fone. Psychopharmacology (Berl) 2011
22
Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.
B Moghaddam, B Adams, A Verma, D Daly. J Neurosci 1997
B Moghaddam, B Adams, A Verma, D Daly. J Neurosci 1997
16
Effects of the mGluR2/3 agonist LY379268 on ketamine-evoked behaviours and neurochemical changes in the dentate gyrus of the rat.
Gabor Imre, Amber Salomons, Minke Jongsma, Dirk S Fokkema, Johan A Den Boer, Gert J Ter Horst. Pharmacol Biochem Behav 2006
Gabor Imre, Amber Salomons, Minke Jongsma, Dirk S Fokkema, Johan A Den Boer, Gert J Ter Horst. Pharmacol Biochem Behav 2006
28
A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models.
Gene G Kinney, Julie A O'Brien, Wei Lemaire, Maryann Burno, Denise J Bickel, Michelle K Clements, Tsing-Bau Chen, David D Wisnoski, Craig W Lindsley, Philip R Tiller,[...]. J Pharmacol Exp Ther 2005
Gene G Kinney, Julie A O'Brien, Wei Lemaire, Maryann Burno, Denise J Bickel, Michelle K Clements, Tsing-Bau Chen, David D Wisnoski, Craig W Lindsley, Philip R Tiller,[...]. J Pharmacol Exp Ther 2005
15
Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites.
Y Tamaru, S Nomura, N Mizuno, R Shigemoto. Neuroscience 2001
Y Tamaru, S Nomura, N Mizuno, R Shigemoto. Neuroscience 2001
15
Effects of a positive allosteric modulator of group II metabotropic glutamate receptors, LY487379, on cognitive flexibility and impulsive-like responding in rats.
Agnieszka Nikiforuk, Piotr Popik, Karla U Drescher, Marcel van Gaalen, Ana-Lucia Relo, Mario Mezler, Gerard Marek, Hans Schoemaker, Gerhard Gross, Anton Bespalov. J Pharmacol Exp Ther 2010
Agnieszka Nikiforuk, Piotr Popik, Karla U Drescher, Marcel van Gaalen, Ana-Lucia Relo, Mario Mezler, Gerard Marek, Hans Schoemaker, Gerhard Gross, Anton Bespalov. J Pharmacol Exp Ther 2010
25
Pharmacological agents acting at subtypes of metabotropic glutamate receptors.
D D Schoepp, D E Jane, J A Monn. Neuropharmacology 1999
D D Schoepp, D E Jane, J A Monn. Neuropharmacology 1999
15
Metabotropic glutamate receptors: electrophysiological properties and role in plasticity.
R Anwyl. Brain Res Brain Res Rev 1999
R Anwyl. Brain Res Brain Res Rev 1999
14
Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2.
Hervé Schaffhauser, Blake A Rowe, Sylvia Morales, Laura E Chavez-Noriega, Ruoyuan Yin, Christine Jachec, Sara P Rao, Gretchen Bain, Anthony B Pinkerton, Jean-Michel Vernier,[...]. Mol Pharmacol 2003
Hervé Schaffhauser, Blake A Rowe, Sylvia Morales, Laura E Chavez-Noriega, Ruoyuan Yin, Christine Jachec, Sara P Rao, Gretchen Bain, Anthony B Pinkerton, Jean-Michel Vernier,[...]. Mol Pharmacol 2003
14
ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities.
Feng Liu, Steve Grauer, Cody Kelley, Rachel Navarra, Radka Graf, Guoming Zhang, Peter J Atkinson, Michael Popiolek, Caitlin Wantuch, Xavier Khawaja,[...]. J Pharmacol Exp Ther 2008
Feng Liu, Steve Grauer, Cody Kelley, Rachel Navarra, Radka Graf, Guoming Zhang, Peter J Atkinson, Michael Popiolek, Caitlin Wantuch, Xavier Khawaja,[...]. J Pharmacol Exp Ther 2008
14
Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment.
Silke Harich, Gerhard Gross, Anton Bespalov. Psychopharmacology (Berl) 2007
Silke Harich, Gerhard Gross, Anton Bespalov. Psychopharmacology (Berl) 2007
16
Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia.
Michael F Egan, Richard E Straub, Terry E Goldberg, Imtiaz Yakub, Joseph H Callicott, Ahmad R Hariri, Venkata S Mattay, Alessandro Bertolino, Thomas M Hyde, Cynthia Shannon-Weickert,[...]. Proc Natl Acad Sci U S A 2004
Michael F Egan, Richard E Straub, Terry E Goldberg, Imtiaz Yakub, Joseph H Callicott, Ahmad R Hariri, Venkata S Mattay, Alessandro Bertolino, Thomas M Hyde, Cynthia Shannon-Weickert,[...]. Proc Natl Acad Sci U S A 2004
14
Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent.
Guy A Higgins, Theresa M Ballard, James N C Kew, J Grayson Richards, John A Kemp, Geo Adam, Thomas Woltering, Shigetada Nakanishi, Vincent Mutel. Neuropharmacology 2004
Guy A Higgins, Theresa M Ballard, James N C Kew, J Grayson Richards, John A Kemp, Geo Adam, Thomas Woltering, Shigetada Nakanishi, Vincent Mutel. Neuropharmacology 2004
14
N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes.
Matthew J Fell, Jeffrey M Witkin, Julie F Falcone, Jason S Katner, Kenneth W Perry, John Hart, Linda Rorick-Kehn, Carl D Overshiner, Kurt Rasmussen, Stephen F Chaney,[...]. J Pharmacol Exp Ther 2011
Matthew J Fell, Jeffrey M Witkin, Julie F Falcone, Jason S Katner, Kenneth W Perry, John Hart, Linda Rorick-Kehn, Carl D Overshiner, Kurt Rasmussen, Stephen F Chaney,[...]. J Pharmacol Exp Ther 2011
17
Glutamate and schizophrenia: beyond the dopamine hypothesis.
Joseph T Coyle. Cell Mol Neurobiol 2006
Joseph T Coyle. Cell Mol Neurobiol 2006
13
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.